Anti-CD25 antibody (Daclizumab) maintenance therapy in pancreas transplantation

Varvara Kirchner, T. M. Suszynski, D. M. Radosevich, A. Humar, Ty B Dunn, M. J. Hill, Erik B Finger, D. E R Sutherland, Raja Kandaswamy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Calcineurin inhibitors (CNI) are the basis of contemporary immunosuppression in clinical pancreas transplantation (PT). Nevertheless, CNI toxicities, especially nephrotoxicity, have stimulated the search for CNI-sparing protocols. We performed a retrospective analysis of 25 PT patients with progressive CNI toxicities that were switched to a daclizumab (DAC)based maintenance regimen. Methods: From 2003 to 2007, 25 PT patients with progressive CNI toxicity (predominantly nephrotoxicity) were identified and switched from CNI to monthly DAC maintenance therapy. The DAC group was compared with matched control subjects (1:1) by transplant type and number, age, year of transplant, and duct management. Results and conclusions: Results showed improved graft survival rates and decreased immunologic loss rates at 1, 3, and 5 years in the DAC group compared with the control group. There was no difference in patient survival rate between the 2 groups. Analysis demonstrates that DAC maintenance therapy is safe and effective for PT patients experiencing CNI toxicities. A randomized trial to compare DAC- and CNI-based regimens is needed in CNI-intolerant patients, with particular attention to the impact on renal function and patient morbidity (eg, infection rates).

Original languageEnglish (US)
Pages (from-to)2003-2005
Number of pages3
JournalTransplantation Proceedings
Volume42
Issue number6
DOIs
StatePublished - Jul 1 2010

Fingerprint

Pancreas Transplantation
Anti-Idiotypic Antibodies
Therapeutics
Survival Rate
Transplants
Calcineurin Inhibitors
daclizumab
Graft Survival
Immunosuppression
Maintenance
Morbidity
Kidney
Control Groups

Cite this

Anti-CD25 antibody (Daclizumab) maintenance therapy in pancreas transplantation. / Kirchner, Varvara; Suszynski, T. M.; Radosevich, D. M.; Humar, A.; Dunn, Ty B; Hill, M. J.; Finger, Erik B; Sutherland, D. E R; Kandaswamy, Raja.

In: Transplantation Proceedings, Vol. 42, No. 6, 01.07.2010, p. 2003-2005.

Research output: Contribution to journalArticle

Kirchner, Varvara ; Suszynski, T. M. ; Radosevich, D. M. ; Humar, A. ; Dunn, Ty B ; Hill, M. J. ; Finger, Erik B ; Sutherland, D. E R ; Kandaswamy, Raja. / Anti-CD25 antibody (Daclizumab) maintenance therapy in pancreas transplantation. In: Transplantation Proceedings. 2010 ; Vol. 42, No. 6. pp. 2003-2005.
@article{ffc58ad23bd14e5a94c6567c41cbe928,
title = "Anti-CD25 antibody (Daclizumab) maintenance therapy in pancreas transplantation",
abstract = "Background: Calcineurin inhibitors (CNI) are the basis of contemporary immunosuppression in clinical pancreas transplantation (PT). Nevertheless, CNI toxicities, especially nephrotoxicity, have stimulated the search for CNI-sparing protocols. We performed a retrospective analysis of 25 PT patients with progressive CNI toxicities that were switched to a daclizumab (DAC)based maintenance regimen. Methods: From 2003 to 2007, 25 PT patients with progressive CNI toxicity (predominantly nephrotoxicity) were identified and switched from CNI to monthly DAC maintenance therapy. The DAC group was compared with matched control subjects (1:1) by transplant type and number, age, year of transplant, and duct management. Results and conclusions: Results showed improved graft survival rates and decreased immunologic loss rates at 1, 3, and 5 years in the DAC group compared with the control group. There was no difference in patient survival rate between the 2 groups. Analysis demonstrates that DAC maintenance therapy is safe and effective for PT patients experiencing CNI toxicities. A randomized trial to compare DAC- and CNI-based regimens is needed in CNI-intolerant patients, with particular attention to the impact on renal function and patient morbidity (eg, infection rates).",
author = "Varvara Kirchner and Suszynski, {T. M.} and Radosevich, {D. M.} and A. Humar and Dunn, {Ty B} and Hill, {M. J.} and Finger, {Erik B} and Sutherland, {D. E R} and Raja Kandaswamy",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.transproceed.2010.05.083",
language = "English (US)",
volume = "42",
pages = "2003--2005",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Anti-CD25 antibody (Daclizumab) maintenance therapy in pancreas transplantation

AU - Kirchner, Varvara

AU - Suszynski, T. M.

AU - Radosevich, D. M.

AU - Humar, A.

AU - Dunn, Ty B

AU - Hill, M. J.

AU - Finger, Erik B

AU - Sutherland, D. E R

AU - Kandaswamy, Raja

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Background: Calcineurin inhibitors (CNI) are the basis of contemporary immunosuppression in clinical pancreas transplantation (PT). Nevertheless, CNI toxicities, especially nephrotoxicity, have stimulated the search for CNI-sparing protocols. We performed a retrospective analysis of 25 PT patients with progressive CNI toxicities that were switched to a daclizumab (DAC)based maintenance regimen. Methods: From 2003 to 2007, 25 PT patients with progressive CNI toxicity (predominantly nephrotoxicity) were identified and switched from CNI to monthly DAC maintenance therapy. The DAC group was compared with matched control subjects (1:1) by transplant type and number, age, year of transplant, and duct management. Results and conclusions: Results showed improved graft survival rates and decreased immunologic loss rates at 1, 3, and 5 years in the DAC group compared with the control group. There was no difference in patient survival rate between the 2 groups. Analysis demonstrates that DAC maintenance therapy is safe and effective for PT patients experiencing CNI toxicities. A randomized trial to compare DAC- and CNI-based regimens is needed in CNI-intolerant patients, with particular attention to the impact on renal function and patient morbidity (eg, infection rates).

AB - Background: Calcineurin inhibitors (CNI) are the basis of contemporary immunosuppression in clinical pancreas transplantation (PT). Nevertheless, CNI toxicities, especially nephrotoxicity, have stimulated the search for CNI-sparing protocols. We performed a retrospective analysis of 25 PT patients with progressive CNI toxicities that were switched to a daclizumab (DAC)based maintenance regimen. Methods: From 2003 to 2007, 25 PT patients with progressive CNI toxicity (predominantly nephrotoxicity) were identified and switched from CNI to monthly DAC maintenance therapy. The DAC group was compared with matched control subjects (1:1) by transplant type and number, age, year of transplant, and duct management. Results and conclusions: Results showed improved graft survival rates and decreased immunologic loss rates at 1, 3, and 5 years in the DAC group compared with the control group. There was no difference in patient survival rate between the 2 groups. Analysis demonstrates that DAC maintenance therapy is safe and effective for PT patients experiencing CNI toxicities. A randomized trial to compare DAC- and CNI-based regimens is needed in CNI-intolerant patients, with particular attention to the impact on renal function and patient morbidity (eg, infection rates).

UR - http://www.scopus.com/inward/record.url?scp=77955530525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955530525&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2010.05.083

DO - 10.1016/j.transproceed.2010.05.083

M3 - Article

VL - 42

SP - 2003

EP - 2005

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 6

ER -